GlassScriptPhysician profile
Sarah L Berga
NPI 1124054218
$26,286.29
in general payments reported to CMS, 2019-2025
8 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,552 · 2021: $896 · 2022: $3,510 · 2023: $14K · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,969 · Travel and Lodging: $5,226 · Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,969.23 |
| Travel and Lodging | $5,225.67 |
| Food and Beverage | $133.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $9,326.55 | 2023-2025 | Myfembree |
| Biogen, INC. | $8,415.00 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $7,516.55 | 2019 | |
| Novo Nordisk Health Care Ag | $880.00 | 2021 | |
| Medtronic, INC. | $80.35 | 2025 | |
| Ferring Research Institute INC. | $35.13 | 2019 | |
| Hologic Sales and Service, LLC | $16.94 | 2025 | Novasure |
| Janssen Pharmaceuticals, INC | $15.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Berga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.